Clinical Trials

Illustration of DNA
Blog Post

FDA Accepts NS Pharma’s NDA for Viltolarsen for the Treatment of DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | February 26, 2020
Blog Post

MDA’s New Chief Research Officer Sharon Hesterlee Shares Vision for the Future

By Jeanene Swanson | February 21, 2020
Blog Post

Roche Genentech Announces Positive Results from Pivotal Study of Risdiplam in SMA Type 1

By Jeanene Swanson | January 31, 2020

Clinical Trial Alert: LGMD2E Participants Sought for a Phase 1/2a Gene Delivery Study

By MDA Staff | January 29, 2020
Blog Post

Clinical Trial Alert: Individuals with SMA Type 3 Sought for a Phase 2 Study

By MDA Staff | January 27, 2020
Blog Post

Antisense Therapeutics Announces Positive Results from Phase 2 Study of ATL1102 in DMD

By Jeanene Swanson | January 24, 2020
Featured Article

Advancing Health, One Research Study at a Time

By Cheryl Alkon | January 15, 2020
Blog Post

MDA Awards More Than $1 Million in Venture Philanthropy Funding to AavantiBio to Develop Gene-Targeting Therapy for Friedreich’s Ataxia

By Jeanene Swanson | January 13, 2020
MDA logo
Blog Post

Mallinckrodt Pharmaceuticals Releases Statement to DMD Community Announcing Discontinuation of Clinical Trials Program for DMD

By MDA Staff | December 20, 2019
Blog Post

Amylyx Pharmaceuticals Announces Positive Results from Phase 2 Study of AMX0035 for Treatment of ALS

By Jeanene Swanson | December 19, 2019